Advisory committee meeting Oct. 12 to discuss NDA for Acelrx's Dsuvia

FDA’s Anesthetic and Analgesic Drug Products Advisory Committee will meet Oct. 12 to discuss an NDA from AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) for Dsuvia sufentanil sublingual tablet (ARX-04) to manage moderate to severe acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults in a medically supervised setting. The NDA has a Nov. 3 PDUFA date.

In October 2017, AcelRx received a complete response letter for Dsuvia (see “AcelRx’s Dsuvia Gets CRL”)...